Skip to main content
Premium Trial:

Request an Annual Quote

Carna Biosciences and CrystalGenomics to Provide Crystallographic Services for Rigel

NEW YORK, June 20 (GenomeWeb News) - Carna Biosciences and CrystalGenomics have signed a joint agreement to provide protein crystallography services for Rigel Pharmaceuticals, the companies said today.


Carna Biosciences, a Japanese biotech that specializes in active kinase protein expression, and CrystalGenomics, a Korean structure-based drug discovery firm, began offering joint crystallographic services in February.


The relationship with Rigel began with the company's purchase of protein kinases from Carna a year ago, Carna Biosciences said.


Financial terms for the agreement were not provided.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.